Researchers analyzed 11 different studies to understand weight outcomes after stopping anti-obesity medications called ...

Reduced monthly costs for uninsured patients still amount to around $500. That can put the drugs out of reach for many.

Researchers in a recent study discovered that people taking medications to help them lose weight might experience weight gain ...

A new study reports that mice shed about 20% of their body weight and saw their breast cancer tumors decrease after getting ...

Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there? Here's what to know.

China's Sciwind Biosciences is in talks with a U.S. company interested in licensing its experimental weight-loss drug for ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor Novo Nordisk, will still be covered under plans managed by CVS Caremark.

Some 20 weeks after stopping their drugs, the participants in the studies had put back on an average of 2.5 kilograms (5.5 ...

Participants who are taking GLP-1 medications and have taken them for at least three months are needed for a study on eating behavior ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. Reduced monthly costs for uninsured patients still amount to around $500.